Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery

Open access
Tejpar, Sabine, Bertagnolli, Monica, Bosman, Fred, Lenz, Heinz-Joseph, Garraway, Levi, Waldman, Frederic, Warren, Robert, Bild, Andrea, Collins-Brennan, Denise, Hahn, Hejin, Harkin, D. Paul, Kennedy, Richard, Ilyas, Mohammad, Morreau, Hans, Proutski, Vitali, Swanton, Charles, Tomlinson, Ian, Delorenzi, Mauro, Fiocca, Roberto, Van Cutsem, Eric, Roth, Arnaud·2010·The Oncologist

Abstract

The number of agents that are potentially effective in the adjuvant treatment of locally advanced resectable colon cancer is increasing. Consequently, it is important to ascertain which subgroups of patients will benefit from a specific treatment. Despite more than two decades of research into the molecular genetics of colon cancer, there is a lack of prognostic and predictive molecular biomarkers with proven utility in this setting. A secondary objective of the Pan European Trials in Adjuvant Colon Cancer-3 trial, which compared irinotecan in combination with 5-fluorouracil and leucovorin in the postoperative treatment of stage III and stage II colon cancer patients, was to undertake a translational research study to assess a panel of putative prognostic and predictive markers in a large colon cancer patient cohort. The Cancer and Leukemia Group B 89803 trial, in a similar design, also investigated the use of prognostic and predictive biomarkers in this setting. In this article, the authors, who are coinvestigators from these trials and performed similar investigations of biomarker discovery in the adjuvant treatment of colon cancer, review the current status of biomarker research in this field, drawing on their experiences and considering future strategies for biomarker discovery in the postgenomic era.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2009-0233

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 185

Metadata

Authors
Tejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., Harkin, D. P., Kennedy, R., Ilyas, M., Morreau, H., Proutski, V., Swanton, C., Tomlinson, I., Delorenzi, M., Fiocca, R., Van Cutsem, E., & Roth, A.
Venue
The Oncologist
Published
2010-03-29
Volume
15
Issue
4
Pages
390-404
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2124003081
Cited by
185
References
12
FWCI
7.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. https://app.cochat.ai/papers/10.1634/theoncologist.2009-0233
The paper
Tejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., Harkin, D. P., Kennedy, R., Ilyas, M., Morreau, H., Proutski, V., Swanton, C., Tomlinson, I., Delorenzi, M., Fiocca, R., . . . Roth, A. (2010). Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. The Oncologist. https://doi.org/10.1634/theoncologist.2009-0233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.